Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomas - AVATAR: Avastin and Temodal attacking relapsed glioma

Academisch Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•1. Patients present with histologically confirmed diagnosis of intracranial recurrent high grade glial tumor (WHO grade IV, including gliosarcomas).
•2. Patients must have evidence of tumor progression following radiation and chemotherapy as measured by MRI (MRI-0 at presentation).
•3. Patients may have received up to two prior chemotherapy regimens (with concurrent radiotherapy).
•4. Patients may have undergone prior surgical resection and will be eligible if recovered from the effects of surgery.
•5. Patients must have adequate organ function.
•6. Patients must have a Karnofsky Performance Score > 70%.
•7. Patients must be > 18 years of age, with a life expectancy of greater than 8 weeks.
•8. Signed informed consent from the patient or legal representative is required.

•9. Patients with inability to comply with protocol or study procedures (for example, an inability to swallow tablets).
•10. Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
•11. Patients receiving EIAEDs (Enzyme-inducing antiepileptic drugs). Patients must discontinue EIAEDs > 14 days prior to study enrollment.
•12. Patients receiving any other anticancer therapy, any anticoagulant therapy.
•13. Patients with serious concomitant systemic disorders that, in opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study.
•14. Patients with prior thrombo-embolic events.

发起方